This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Santarus, Inc. And Salix Pharmaceuticals, Ltd. Merger May Not Be In Santarus, Inc. Shareholders' Best Interests

SAN DIEGO, Nov. 8, 2013 /PRNewswire/ -- Shareholder rights attorneys at Robbins Arroyo LLP are investigating the proposed acquisition of Santarus, Inc. (NASDAQ: SNTS) by Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP).  Santarus and Salix announced the signing of a definitive merger agreement pursuant to which Salix will acquire Santarus.  Under the terms of the agreement, holders of Santarus will receive $32.00 in cash for each share owned.


Is the Merger Best for Santarus and Its Shareholders?

Robbins Arroyo LLP's investigation focuses on whether the board of directors at Santarus is undertaking a fair process to obtain maximum value and adequately compensate Santarus shareholders in the merger.  Notably, Santarus is currently experiencing success and growth in its business prospects, as indicated in its November 7, 2013 press release announcing the company's financial results for its third quarter 2013.  In particular, Santarus reported substantial increases in:
  • Total revenue growth of 81% to $98.8 million, compared to 54.7% million for the same quarter 2012;
  • Net income growth of 236% to $30.3 million, compared to $9.0 million for the same quarter 2012; and
  • Cash, cash equivalents, and short-term investments growth of 78% to $168.7 million as of September 30, 2013, compared with $94.7 million at December 31, 2012.

Additionally, the officers and directors, who collectively own 12% of the outstanding shares of the company, have agreed to vote in favor of the merger and vote against any alternative transaction. 

Given these facts, Robbins Arroyo LLP is examining the Santarus board of directors' decision to sell the company to Salix now rather than allow shareholders to continue to participate in the company's continued success and future growth prospects, and whether they are seeking to benefit themselves.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $95.03 0.21%
FB $116.73 0.00%
GOOG $691.02 0.00%
TSLA $247.54 -0.07%
YHOO $36.59 0.00%


Chart of I:DJI
DOW 17,830.76 -210.79 -1.17%
S&P 500 2,075.81 -19.34 -0.92%
NASDAQ 4,805.2910 -57.85 -1.19%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs